Enterobacteriaceae strains having elevated minimal inhibitory concentrations (.2.0 to s32 ,ug/ml) of cefoperazone, cefotaxime, ceftazidime, and moxalactam were synergistically inhibited by amikacin combinations (54.1 to 69.6% occurrence). Indifference was rare (8.1% for moxalactam), and true antagonistic interactions were not observed. Strains resistant or susceptible to these new cephalosporins were also synergistically inhibited by the addition of amikacin, reducing resistant cephalosporin minimal inhibitory concentrations to clinically achievable levels.
Amikacin has been recognized as the currently available aminoglycoside most refractory to bacterial enzyme inactivation (18) . This stability has generally limited the use of amikacin to those clinical bacterial strains resistant to kanamycin, gentamicin, and tobramycin by enzyme plasmid-mediated mechanisms. Similarly, the recently introduced third-generation cephalosporins have substantial stability to bacterial plactamases and a potent antimicrobial activity (2, 3, 6-9, 15, 16) . The bacteria most likely to harbor the higher minimal inhibitory concentrations (MICs) for these new ,B-lactams are the nonfermentative bacilli and the serogroup D Streptococcus spp.; however, a few strains of Enterobacteriaceae may have MICs of 2.0 to 32 ,ug/ml (3, (7) (8) (9) . These latter organisms represent a very different population of enteric bacilli only moderately susceptible (MS) to these highly active new drugs. Very few Enterobacteriaceae are currently considered resistant (MICs, .64 ,g/ml) to cefoperazone,' cefotaxime, ceftazidime, or moxalactam.
To determine the possibility of using antimicrobial combinations to treat infections caused by these MS strains of Enterobacteriaceae (cefoperazone, cefotaxime, ceftazidime, or moxalactam MICs, 2.0 to 32 ,ug/ml), we screened over 6,000 organisms to find strains having elevated were also tested for synergy, although enhanced inhibitory activity was technically difficult to determine on such isolates (2, 6, 15, 16) .
Antibiotic susceptibility tests and synergy studies.
The MIC screening phase and the retesting of strains were performed by dilution susceptibility tests, using methods described previously and published in the latest edition (tentative standard) of the National Committee for Clinical Laboratory Standards (NCCLS) dilution methods (3, 14) . In the screening tests, two antimicrobial concentrations were used for each drug (1.0 and 32 ±g/ml for cefotaxime, ceftazidime, and moxalactam; 2.0 and 64 ,ug/ml for cefoperazone), and those Enterobacteriaceae isolates ultimately having MICs of .2.0 and c32 F±g/ml were selected for synergy studies at The Clinical Microbiology Institute, Tualatin, Oreg.
For the checkerboard technique, broth microdilution synergy trays were prepared in plastics (Dynatech Laboratories, Inc., Alexandria, Va.), in which amikacin was combined with each of the new 1-lactams.
Methods described previously, using divalent cationsupplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) (6, 14) , were employed. Each test strain was inoculated into the plastic trays at a final density of 5 x 10' colony-forming units per ml and then incubated overnight (15 to 20 h), read as MICs, and plotted as isobolograms. Minimal bactericidal concentration isobolograms and kill curves were randomly performed to confirm (internal quality control) the interpretive validity of the use of inhibitory endpoints against Enterobacteriaceae (6). Approximately 10% of the well volumes (0.01 ml) was subcultured after tray agitation to drug-free 5% sheep blood agar plates. The minimal bactericidal concentration was defined as the lowest concentration resulting in a .99.9% reduction in the original inoculum concentration (<5 x 102 colony-forming units per ml) by the criteria of Pearson et al. (17) . Kill curves (inoculum, 5 x 105 colony-forming units per ml) were performed in 2 ml of Mueller-Hinton broth combining one-fourth of the MIC of amikacin and the MIC of the other drug. A synergistic bactericidal endpoint was defined as .99%6 superior reduction in colony-forming units at 24 h compared with the ,3-lactam concentration alone (10) .
Data confirmed the comparability of the previously documented methods of results to within one interpretive category (6) .
A total of 216 drug synergy studies were performed in which amikacin was combined with P-lactams. The criteria for synergy were the graphic concavity of the isobologram plots and a fourfold or more decrease in the MIC of one antimicrobial agent when combined with a concentration equivalent to one-fourth of the MIC of the other. The additive interaction was defined as a fourfold or greater decrease in the MIC of one agent and a twofold reduction in the MIC of the other drug (sometimes called partial synergy) or as a twofold decrease in the MICs of both tested drugs. Indifference was defined as no significant decrease in the MIC of either compound or only a twofold decrease or increase in the MIC of one drug. Antagonism was defined as a fourfold or greater increase in the MICs of either or both antimicrobial agents (6) . A clinically meaningful synergy would imply that each antimicrobial agent must have an MIC of, or reduced to, a drug level readily achievable in serum or tissue with the usual recommended dose. Synergy would also be considered of questionable significance if both drugs were highly active against a strain when tested singly.
The significance of the synergy results between the drug combinations were determined by the chi-square test. Data on the incidence of MICs of antimicrobial agents were taken from earlier, more extensive studies of Enterobacteriaceae (4,679 to 8,038 consecutive clinical isolates) from six geographically separated medical centers in comparative in vitro investigations of cefoperazone, cefotaxime, ceftazidime, and moxalactam (3, 7-9; see Table 1 ). Similar data were derived for amikacin from in vitro studies of fortimicin A (5).
RESULTS
The number of isolates found in the susceptibility screening phase of this study were examined for comparability with previous geographically dispersed clinical bacterial samples ( (14) . Data were modified from published studies (3, 5, (7) (8) (9) 16 ,g/ml (tentative) for ceftazidime (7) .
were seen among the C. freundii and Enterobacter aerogenes strains; the lower rates of synergy for moxalactam were found for the C. freundii and Enterobacter cloacae isolates, and 3 of 8 non-synergy interactions with ceftazidime were found for Enterobacter aerogenes strains. Only moxalactam showed a lack of enhanced killing (indifference) for one strain each of Escherichia coli, Enterobacter aerogenes, and C. freundii. By the commonly used fractional inhibitory concentration index of .2.0 for antagonistic definition, the three moxalactam-amikacin studies show antagonism (10 (2, 13, 15, 20) . Moreover, synergy has proven to be valuable for the treatment of some infected patient populations, especially those with leukopenia and compromised immune mechanisms (12, 20) . It also seems critical to select the antimicrobial agents that are compatible in vitro and in vivo. Amikacin has proven to be among the least inactivated aminoglycosides by high ,-lactam concentrations (4). The results of this in vitro trial provide evidence that amikacin used in combination with either cefotaxime, cefoperazone, ceftazidime, or moxalactam will produce high rates of clinically meaningful synergy against those Enterobacteriaceae isolates most likely to require multiple drug therapy. These data confirm an earlier trend toward slightly lower synergy rates with moxalactam-aminoglycoside combinations and the fact that synergy rates are usually highest for the organism having elevated MICs for the individual antibiotics. Combining amikacin and third-generation cephalosporin provides the broadest-spectrum empirical coverage for serious clinical infections among currently available drugs. Comparable antimicrobial coverage and synergy might be expected substituting other aminoglycosides, but this possibility will require supporting studies against a similarly selected organism population (R. N. Jones, manuscript in preparation).
